Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

We assessed safety and efficacy of rituximab in a prospective study of 36 patients, age 2.6 to 18.3 years, with severe chronic immune thrombocytopenic purpura (ITP). The primary outcome of sustained platelets above 50 × 10(9)/L (50 000/mm(3)) during 4 consecutive weeks, starting in weeks 9 to 12, wa...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Bennett, Carolyn M., Rogers, Zora R., Kinnamon, Daniel D., Bussel, James B., Mahoney, Donald H., Abshire, Thomas C., Sawaf, Hadi, Moore, Theodore B., Loh, Mignon L., Glader, Bertil E., McCarthy, Maggie C., Mueller, Brigitta U., Olson, Thomas A., Lorenzana, Adonis N., Mentzer, William C., Buchanan, George R., Feldman, Henry A., Neufeld, Ellis J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: The American Society of Hematology 2006
Θέματα:
Clinical Trials and Observations
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895391/
https://ncbi.nlm.nih.gov/pubmed/16352811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-08-3518
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια